Rybelsus, the first oral GLP-1 receptor agonist, opened a new chapter in diabetes management. This innovative medication primarily targets blood sugar control by mimicking the effects of the incretin hormone, GLP-1. By activating GLP-1 receptors in the pancreas, Rybelsus stimulates insulin secretion in response to meals, effectively lowering blood sugar…